Bayer and Onyx have launched a number of clinical trials in breast cancer. For a more comprehensive list of sorafenib clinical trials, please visit clinicaltrials.gov or call 866-738-3021.
Study Design: Randomized, double-blind, placebo-controlled trial
Patients:Locally advanced or metastatic HER2 negative breast cancer patients who have failed prior taxane and an anthracycline containing chemotherapy regimen or for whom further anthraycycline therapy is not indicated and have failed no more than one prior chemo for locally advanced or metastatic disease
Purpose: To determine the effectiveness of sorafenib in combination with capecitabine vs. capecitabine alone by assessing the difference in progression-free survival (PFS). In addition, the study will evaluate other measures of efficacy and safety
Location: Multiple centers throughout the United States, Europe, Russia, Latin America, and the Asia-Pacific region